Travere Therapeutics, Inc.
TVTX
$42.84
-$0.67-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 96.03% | 110.46% | 114.22% | 87.94% | 75.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.03% | 110.46% | 114.22% | 87.94% | 75.65% |
| Cost of Revenue | 4.34% | 1.57% | 3.57% | -0.30% | -2.75% |
| Gross Profit | 716.36% | 3,201.26% | 1,044.26% | 280.93% | 139.43% |
| SG&A Expenses | 32.39% | 22.97% | 13.31% | 4.36% | -1.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.98% | 13.12% | 8.78% | 2.16% | -2.02% |
| Operating Income | 74.65% | 75.48% | 67.92% | 46.03% | 36.26% |
| Income Before Tax | 80.17% | 84.63% | 74.61% | 55.86% | 45.61% |
| Income Tax Expenses | 2,690.63% | 723.33% | -101.92% | -127.25% | -109.52% |
| Earnings from Continuing Operations | 79.80% | 84.32% | 74.63% | 55.93% | 45.66% |
| Earnings from Discontinued Operations | 3,082.14% | 2,801.09% | 100.16% | -100.02% | -100.32% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.55% | 92.06% | 74.81% | -15.86% | -40.70% |
| EBIT | 74.65% | 75.48% | 67.92% | 46.03% | 36.26% |
| EBITDA | 109.01% | 99.02% | 85.33% | 56.18% | 42.64% |
| EPS Basic | 91.84% | 92.89% | 77.02% | -8.73% | -33.93% |
| Normalized Basic EPS | 82.37% | 82.75% | 70.67% | 49.19% | 37.52% |
| EPS Diluted | 91.39% | 92.58% | 76.73% | -8.76% | -33.96% |
| Normalized Diluted EPS | 81.01% | 81.58% | 69.60% | 49.19% | 37.52% |
| Average Basic Shares Outstanding | 10.28% | 13.09% | 13.19% | 10.01% | 6.81% |
| Average Diluted Shares Outstanding | 14.38% | 17.33% | 17.53% | 10.01% | 6.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |